Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
Arvind Gharbharan, Corine H. GeurtsvanKessel, Carlijn Jordans, Marc J. T. Blaauw, Marjolein van der Klift, Robert‐Jan Hassing, Marijn Smits-Zwinkels, Maaike Meertens, Ella C van den Hout, Anne Marie de Man, Ilse M.G. Hageman, Susanne Bogers, C. Ellen van der Schoot, Francis Swaneveld, Adam A. Anas, Casper Rokx, Bart Rijnders
Abstract
Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.
Topics & Concepts
MedicineConvalescent plasmaAntibodyCoronavirusTiterCoronavirus disease 2019 (COVID-19)DiseasePopulationVirologyNeutralizing antibodyCD19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInternal medicineGastroenterologyInfectious disease (medical specialty)Environmental healthSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesChronic Lymphocytic Leukemia Research